Table of Contents Author Guidelines Submit a Manuscript
Interdisciplinary Perspectives on Infectious Diseases
Volume 2009, Article ID 195040, 5 pages
http://dx.doi.org/10.1155/2009/195040
Review Article

Chemotherapy of Human African Trypanosomiasis

Department of Biological and Health Sciences, Haskins Laboratory, Pace University, New York, NY 10038, USA

Received 27 March 2009; Accepted 28 April 2009

Academic Editor: Louis M. Weiss

Copyright © 2009 Cyrus J. Bacchi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. M. Fèvre, K. Picozzi, J. Fyfe et al., “A burgeoning epidemic of sleeping sickness in Uganda,” The Lancet, vol. 366, no. 9487, pp. 745–747, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. V. W. Pentreath, “Trypanosomiasis and the nervous system: pathology and immunology,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 1, pp. 9–15, 1995. View at Publisher · View at Google Scholar
  3. J. M. Sternberg, “Immunobiology of African trypanosomiasis,” Chemical Immunology, vol. 70, pp. 186–199, 1998. View at Publisher · View at Google Scholar
  4. J. E. Donelson, K. L. Hill, and N. M. A. El-Sayed, “Multiple mechanisms of immune evasion by African trypanosomes,” Molecular and Biochemical Parasitology, vol. 91, no. 1, pp. 51–66, 1998. View at Publisher · View at Google Scholar
  5. “Drugs for parasitic infections,” The Medical Letter on Drugs and Therapeutics, vol. 40, no. 1017, pp. 1–12, 1998.
  6. J. Pépin and F. Milord, “The treatment of human African trypanosomiasis,” Advances in Parasitology, vol. 33, pp. 1–47, 1994. View at Publisher · View at Google Scholar
  7. S. Gehrig and T. Efferth, “Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human Africa trypanosomiasis with natural products (review),” International Journal of Molecular Medicine, vol. 22, no. 4, pp. 411–419, 2008. View at Publisher · View at Google Scholar
  8. F. Chappuis, “Melarsoprol-free drug combinations for second-stage gambian sleeping sickness: the way to go,” Clinical Infectious Diseases, vol. 45, no. 11, pp. 1443–1445, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. G. Priotto and A.-M. Sevscik, “An improved treatment for sleeping sickness,” DNDi Newsletter, no. 17, pp. 1–2, 2008. View at Google Scholar
  10. M. P. Barrett, D. W. Boykin, R. Brun, and R. R. Tidwell, “Human African trypanosomiasis: pharmacological re-engagement with a neglected disease,” British Journal of Pharmacology, vol. 152, no. 8, pp. 1155–1171, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. C. C. Wang, “Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis,” Annual Review of Pharmacology and Toxicology, vol. 35, no. 11, pp. 93–127, 1995. View at Publisher · View at Google Scholar · View at PubMed
  12. A. H. Fairlamb, N. S. Carter, M. Cunningham, and K. Smith, “Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism,” Molecular and Biochemical Parasitology, vol. 53, no. 1-2, pp. 213–222, 1992. View at Publisher · View at Google Scholar
  13. N. S. Carter, B. J. Berger, and A. H. Fairlamb, “Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen- sensitive and -resistant Trypanosoma brucei brucei,” The Journal of Biological Chemistry, vol. 270, no. 47, pp. 28153–28157, 1995. View at Publisher · View at Google Scholar
  14. H. P. de Koning, “Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals,” Molecular Pharmacology, vol. 59, no. 3, pp. 586–592, 2001. View at Google Scholar
  15. V. Delespaux and H. P. de Koning, “Drugs and drug resistance in African trypanosomiasis,” Drug Resistance Updates, vol. 10, no. 1, pp. 30–50, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. E. L. M. Vansterkenburg, I. Coppens, J. Wilting et al., “The uptake of the trypanocidal drug suramin in combination with low- density lipoproteins by Trypanosoma brucei and its possible mode of action,” Acta Tropica, vol. 54, no. 3-4, pp. 237–250, 1993. View at Publisher · View at Google Scholar
  17. G. Priotto, C. Fogg, M. Balasegaram et al., “Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda,” PLoS Clinical Trials, vol. 1, no. 8, article e39, pp. 1–8, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. A. H. Fairlamb, P. Blackburn, P. Ulrich, B. T. Chait, and A. Cerami, “Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids,” Science, vol. 227, no. 4693, pp. 1485–1487, 1985. View at Google Scholar
  19. A. H. Fairlamb, G. B. Henderson, C. J. Bacchi, and A. Cerami, “In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei,” Molecular and Biochemical Parasitology, vol. 24, no. 2, pp. 185–191, 1987. View at Publisher · View at Google Scholar
  20. A. H. Fairlamb, G. B. Henderson, and A. Cerami, “Trypanothione is the primary target for arsenical drugs against African trypanosomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 8, pp. 2607–2611, 1989. View at Google Scholar
  21. C. J. Bacchi, H. C. Nathan, S. H. Hutner, P. P. McCann, and A. Sjoerdsma, “Polyamine metabolism: a potential therapeutic target in trypanosomes,” Science, vol. 210, no. 4467, pp. 332–334, 1980. View at Publisher · View at Google Scholar
  22. S. Van Nieuwenhove, “Advances in sleeping sickness therapy,” Annales de la Société Belge de Médecine Tropicale, vol. 72, supplement 1, pp. 39–51, 1992. View at Google Scholar
  23. G. Priotto, L. Pinoges, I. B. Fursa et al., “Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study,” British Medical Journal, vol. 336, no. 7646, pp. 705–708, 2008. View at Publisher · View at Google Scholar · View at PubMed
  24. F. Checchi, P. Piola, H. Ayikoru, F. Thomas, D. Legros, and G. Priotto, “Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series,” PLoS Neglected Tropical Diseases, vol. 1, no. 2, article e64, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. C. J. Bacchi and N. Yarlett, “Polyamine metabolism,” in Biochemistry and Molecular Biology of Parasites, J. J. Marr and M. Müller, Eds., pp. 119–131, Academic Press, New York, NY, USA, 1995. View at Google Scholar
  26. C. J. Bacchi, J. Garofalo, D. Mockenhaupt et al., “In vivo effects of α-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei,” Molecular and Biochemical Parasitology, vol. 7, no. 3, pp. 209–225, 1983. View at Google Scholar
  27. A. J. Bitonti, P. P. McCann, and A. Sjoerdsma, “Necessity of antibody response in the treatment of African trypanosomiasis with α-difluoromethylornithine,” Biochemical Pharmacology, vol. 35, no. 2, pp. 331–334, 1986. View at Google Scholar
  28. C. J. Bacchi, H. C. Nathan, T. Livingston et al., “Differential susceptibility to DL-α-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense,” Antimicrobial Agents and Chemotherapy, vol. 34, no. 6, pp. 1183–1188, 1990. View at Google Scholar
  29. A. J. Bitonti, C.J. Bacchi, , PP. McCann, and A. Sjoerdsma, “Uptake of a-difluoromethylornithine by Trypanosoma brucei bruci,” Biochemical Pharmacology, vol. 35, pp. 3541–3545, 1986. View at Google Scholar
  30. M. Iten, H. Mett, A. Evans, J. C. K. Enyaru, R. Brun, and R. Kaminsky, “Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-α- difluoromethylornithine,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 9, pp. 1922–1925, 1997. View at Google Scholar
  31. M. A. Phillips, P. Coffino, and C. C. Wang, “Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei,” Molecular and Biochemical Parasitology, vol. 22, no. 1, pp. 9–17, 1987. View at Google Scholar
  32. L. Ghoda, M. A. Phillips, K. E. Bass, C. C. Wang, and P. Coffino, “Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellualr degradation,” The Journal of Biological Chemistry, vol. 265, no. 20, pp. 11823–11826, 1990. View at Google Scholar
  33. F. Chappuis, N. Udayraj, K. Stietenroth, A. Meussen, and P. A. Bovier, “Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis,” Clinical Infectious Diseases, vol. 41, no. 5, pp. 748–751, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. G. Priotto, S. Kasparian, D. Ngouama et al., “Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo,” Clinical Infectious Diseases, vol. 45, no. 11, pp. 1435–1442, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. A. B. Clarkson Jr., E. J. Bienen, C. J. Bacchi, P. P. McCann, S. H. Hutner, and A. Sjoerdsma, “New drug combination for experimental late-stage African trypanosomiasis: DL-α-difluoromethylornithine (DFMO) with suramin,” The American Journal of Tropical Medicine and Hygiene, vol. 33, no. 6, pp. 1073–1077, 1984. View at Google Scholar
  36. C. J. Bacchi, H. C. Nathan, N. Yarlett et al., “Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-α-difluoromethylornithine and standard trypanocides,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 3, pp. 563–569, 1994. View at Google Scholar
  37. C. J. Bacchi, H. C. Nathan, A. B. Clarkson Jr. et al., “Effects of the ornithine decarboxylase inhibitors DL-α-difluoromethylornithine and 3,4 dehydromonofluoromethylornithine alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models,” The American Journal of Tropical Medicine and Hygiene, vol. 35, pp. 46–52, 1987. View at Google Scholar
  38. M. O. Eze, “Towards more efficacious chemotherapy of trypanosomiasis: combination of α-difluoromethylornithine (DFMO) with reactive oxygen generating drugs,” Medical Hypotheses, vol. 36, no. 3, pp. 246–249, 1991. View at Publisher · View at Google Scholar